SEOM clinical guideline on heritable TP53-related cancer syndrome (2022)

por Sánchez-Heras, Ana Beatriz, Ramon y Cajal, Teresa, Pineda, Marta, Aguirre, Elena, Graña, Begoña, Chirivella, Isabel, Balmaña, Judit, Brunet, Joan
Publicado 2023

Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)

por Blanch, Salvador, Gil-Gil, Juan Miguel, Arumí, Miriam, Aguirre, Elena, Seguí, Miguel Ángel, Atienza, Manuel, Díaz-Cerezo, Silvia, Molero, Alberto, Cervera, José Manuel, Gavilá, Joaquín
Publicado 2023

Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design

por Sampayo-Cordero, Miguel, Miguel-Huguet, Bernat, Pérez-García, José, Páez, David, Guerrero-Zotano, Ángel L., Garde-Noguera, Javier, Aguirre, Elena, Holgado, Esther, López-Miranda, Elena, Huang, Xin, Malfettone, Andrea, Llombart-Cussac, Antonio, Cortés, Javier
Publicado 2020

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIF...

por Di Cosimo, Serena, Pérez-García, José Manuel, Bellet, Meritxell, Dalenc, Florence, Gil Gil, Miguel J, Ruiz Borrego, Manuel, Gavilá, Joaquín, Sampayo-Cordero, Miguel, Aguirre, Elena, Schmid, Peter, Marmé, Frederik, Gligorov, Joseph, Schneeweiss, Andreas, Albanell, Joan, Zamora, Pilar, Wheatley, Duncan, Martínez-De Dueñas, Eduardo, Carañana, Vicente, Amillano, Kepa, Mina, Leonardo, Malfettone, Andrea, Cortés, Javier, Llombart-Cussac, Antonio
Publicado 2022

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2(+) breast cancer

por Jacobs, Samuel A., Robidoux, André, Abraham, Jame, Pérez-Garcia, José Manuel, La Verde, Nicla, Orcutt, James M., Cazzaniga, Marina E., Piette, Fanny, Antolín, Silvia, Aguirre, Elena, Cortes, Javier, Llombart-Cussac, Antonio, Di Cosimo, Serena, Kim, Rim S., Feng, Huichen, Lipchik, Corey, Lucas, Peter C., Srinivasan, Ashok, Wang, Ying, Song, Nan, Gavin, Patrick G., Balousek, April D., Paik, Soonmyung, Allegra, Carmen J., Wolmark, Norman, Pogue-Geile, Katherine L.
Publicado 2019

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ br...

por Jacobs, Samuel A., Robidoux, André, Abraham, Jame, Pérez-Garcia, José Manuel, La Verde, Nicla, Orcutt, James M., Cazzaniga, Marina E., Piette, Fanny, Antolín, Silvia, Aguirre, Elena, Cortes, Javier, Llombart-Cussac, Antonio, Di Cosimo, Serena, Kim, Rim S., Feng, Huichen, Lipchik, Corey, Lucas, Peter C., Srinivasan, Ashok, Wang, Ying, Song, Nan, Gavin, Patrick G., Balousek, April D., Paik, Soonmyung, Allegra, Carmen J., Wolmark, Norman, Pogue-Geile, Katherine L.
Publicado 2020

Palbociclib combined with endocrine therapy in heavily pretreated HR(+)/HER2(-) advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

por Manso, Luis, Hernando, Cristina, Galán, María, Oliveira, Mafalda, Cabrera, Miguel A., Bratos, Raquel, Rodríguez, César A., Ruiz-Borrego, Manuel, Blanch, Salvador, Llombart-Cussac, Antonio, Delgado-Mingorance, Juan I., Álvarez-Busto, Iñaki, Gallegos, Isabel, González-Cortijo, Lucía, Morales, Serafín, Aguirre, Elena, Hernando, Blanca A., Ballesteros, Ana, Alés-Martínez, José E., Reboredo, Cristina, Oltra, Amparo, González-Cao, María, Santisteban, Marta, Malón, Diego, Echeverría, Isabel, García-Garre, Elisa, Vega, Estela, Servitja, Sònia, Andrés, Raquel, Robles, Carlos E., López, Rafael, Galve, Elena, Echarri, María J., Legeren, Marta, Moreno, Fernando
Publicado 2020